Breaking News

Abbott Acquires Kos Pharmaceuticals

Abbott has acquired a majority of the shares of Kos Pharmaceuticals, Inc. for $3.7 billion. The acquisition follows a scheduled expiration on December 12th for the purchase of all outstanding common stock of Kos. Abbott’s shares now represent approximately 91.4% of Kos’ outstanding shares.

The merger is expected to occur within the next few days.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters